Czech Republic

2020 Edition


Home to a USD 3.38 billion pharma market, one of Central and Eastern Europe’s most high-performing healthcare systems, and one of the region’s leading economies, the Czech Republic’s healthcare and life sciences market is fast closing the gap on its Western European equivalents.

A traditionally tightly regulated domestic market is undergoing reform, and a more amenable administration is putting in place a system more conducive to the latest medical innovations. Notable progress has been made in the fields of preventative medicine, cutting-edge oncology treatments, and orphan drugs.

However, the country’s reference pricing system, whereby reimbursement is set based on the lowest price in the EU acts as a significant impediment to the introduction of both innovative and generic drugs alike to the Czech market.

The Czech Republic is staking a name for itself as a prime investment location, situated at the heart of Europe and with strong connections to the rest of the continent and beyond. Moreover, several multinational firms are setting up regional hubs and service centres in the capital, Prague, as well as centres of excellence for research and clinical trials in key therapeutic areas such as oncology.

Other key topics covered in this comprehensive new report include the country’s medical device sector, how the patient voice is increasingly being heard in the decision-making process, a burgeoning medical aesthetics segment, and much more.

Read the Full Version

Adam Vojtěch

Minister of Health, Czech Republic

Dear esteemed readers,

Healthcare impacts all of us – sooner or later each and every one of us will need medical care. Close to CZK 350 billion (EUR 13.7 billion) of funds flow into this sector in 2020, and with an ageing population, this will inevitably lead to a rise in care expenses. In order to ensure the long-term viability of the healthcare system, the current administration is committed to continually improving its efficiency, quality, and transparency.

Our goal is to successfully implement the Health 2030 Strategic Framework based on three strategic pillars: improving the health of the population, optimizing the healthcare system and supporting science and research. As part of the optimization of the healthcare system, primary care will gradually be transformed, with the reinforcement of the role of general practitioners, and a strengthening of communal and home care. Through this transformation, it is our hope that primary care will be able to provide broad yet high-quality care, easily accessible to every patient, while ensuring the sustainable long-term management of patients with chronic illnesses. We will also continue to promote health protection and disease prevention.

We have already made significant progress towards these goals, especially by closing the gap in healthcare digitalization. The first step was the successful roll-out of mandatory electronic prescription system eRecept. Moreover, a major overhaul of the National Health Information System has been completed, with interconnected registries equipping health authorities, insurance funds and care providers with a wealth of real-world evidence to support decisions on the organization and funding of reimbursement, treatment, and care.

Supporting science and research will be key to addressing priority tasks. As part of the Innovation Strategy of the Czech Republic 2019–2030, the government aims to make the Czech Republic one of the leading innovative countries in Europe in different fields, including healthcare and life sciences, by significantly increasing investments in research and development, building the necessary infrastructure, and attracting the right talent, to essentially bring together scientists with leading pharmaceutical and academic specialists.

Finally, with support from the WHO and European partners, we are addressing the availability and affordability of medicines. For instance, tackling the issue of shortages by addressing drug manufacturing and delivery problems. To improve affordability, we are partnering with our V4 neighbors: Poland, Hungary, and Slovakia, to share information on drug prices and jointly negotiate with manufacturers.

We will take on the challenges of tomorrow with a continued focus on people’s equal worth, on collective principles, and on cost-effectiveness. Opportunities deriving from digitalization coupled with increased collaboration between academia, healthcare, and industry stakeholders will lead to improved, evidence-based and cost-efficient health and medical care. As Minister of Health, I am pleased to introduce the 2020 edition of the Czech Republic Healthcare & Life Sciences Review which shines a light on the innovative and collaborative ways the country is tackling tomorrow’s health challenges in the present day.

Adam Vojtěch

Minister of Health

Government of the Czech Republic

Featured Content
Cover Story
Closing the Gap

Although dwarfed in size by some of the biggest economies in Europe with which it shares its borders, the Czech Republic is one of the Central and Eastern European (CEE) region’s best-performing economies. Indeed, on a per capita level, the Czechs are well ahead of their CEE neighbors, with GDP (PPP) per capita standing at USD 39,337 in 2019.Moreover, the Czechs can proudly boast one of the best healthcare systems in the CEE; despite healthcare expenditure as a percentage of GDP standing at 7.2 percent compared to an EU average of 9.8 percent. A universal healthcare system funded by seven insurance companies covers the healthcare needs of the vast majority of the country’s ten million citizens.

Facts & Figures

Thanks for reading!

The Digital Version of the Healthcare & Life Sciences Review: Czech Republic is available and optimized for desktop browsers.

Visit our website with your computer or download the pdf report

Read the Full Version

2020. Healthcare & Life Sciences Review was produced by Pharmaboardroom.

Copyright: All rights reserved. No part of this publication maybe reproduced in any form or by any means, whether electronic, mechanical or otherwise including photocopying, recording or any information storage or retrieval system without prior written consent of PharmaBoardroom. While every attempt is made to ensure the accuracy of the information contained in this report, neither PharmaBoardroom nor the authors accept any liabilities for errors and omissions. Opinions expressed in this report are not necessarily those of the authors. All the images belongs to its respective authors.

Report Director: Georgina Lott
Report Editor: Guillaume Le Maut
Report Coordinator: Delphine Lemercier
Senior Editor: Patrick Burton
Publisher: Mariuca Georgescu
Graphic Designer: Miriam León


Contact us

+44 20 7867 3717

For media inquiries, please contact:


PharmaBoardroom Limited Lynton House, 7-12, Tavistock Square, London, United Kingdom, WC1H 9LT